Filed
by Natura Holding S.A.
Pursuant
to Rule 425 of the Securities Act of 1933
Subject
Company:
Avon
Products, Inc.
(Commission
File No.: 1-4881)
The
following is a press release by Natura Cosméticos S.A. on July 26, 2019:
Natura
Cosméticos S.A. Announces Expiration and Receipt of Requisite Consents with respect to the Consent Solicitation for the
Avon Products, Inc. Notes due 2023 and Extension of the Consent Solicitation for the Avon Products, Inc. Notes due 2043
São
Paulo, Brazil, July 26, 2019 —
Natura Cosméticos S.A. (“
Natura”
or the “Company”) announced today the expiration of its previously announced solicitation (the “2023s Consent
Solicitation”) of consents on behalf of Avon Products, Inc. (“Avon” or the “Issuer”) and receipt
of requisite consents from holders (the “2023s Holders”) necessary to effect the amendments (the “2023s Amendments”)
to the indenture governing Avon’s outstanding 5.000% Notes due 2023 (the “2023 Notes”), as described in the
Consent Solicitation Statement, dated
July 19, 2019
(the “Consent Solicitation
Statement”). In connection with the 2023s Consent Solicitation, the Issuer and the trustee will enter into a supplemental
indenture (the “2023s Supplemental Indenture”) to the indenture governing the 2023 Notes to effect the 2023s Amendments.
The
2023s Consent Solicitation expired at 5:00 P.M. New York City time, on
July
25, 2019
(the “2023s Expiration Date”). The Company received the requisite
consent
from 2023s Holders, and such consents had not been validly revoked prior to the 2023s Expiration Date. The Company will pay the
consent fee payable to 2023s Holders
who delivered valid and unrevoked consents to the 2023s
Amendments on or prior to the
2023s Expiration Date in an amount equal to U.S.$2.50 per U.S.$1,000 aggregate principal
amount of the 2023 Notes(the “2023s Consent Fee”) to The Depository Trust Company for the benefit of the applicable
2023s Holders
as of 5:00 P.M. New York City time, on
July 18, 2019
(the
“2023s Record Date”), subject to the terms and conditions set forth in the Consent Solicitation Statement. The Company
expects to pay, or cause to be paid, the 2023s Consent Fee on July 29, 2019
(such date with respect to the 2023 Notes,
the “2023s Settlement Date”). No accrued interest will be paid in respect of the 2023s Consent Fee.
The
2023s Supplemental Indenture and the related 2023s Amendments will become effective immediately upon execution of the 2023s Supplemental
Indenture and will be operative upon the 2023s Settlement Date. All 2023s Holders are bound by the terms of the 2023s Supplemental
Indenture, including those that did not give their consent. However, 2023s Holders who did not deliver consents on or prior to
the 2023s Expiration Date (or who delivered consents but validly revoked them prior to the 2023s Expiration Date) will not receive
the 2023s Consent Fee
.
In
addition, the Company announced today that it has extended the expiration date of its previously announced solicitation (the “2043s
Consent Solicitation”) of consents on behalf of the Issuer from holders (the “2043s Holders”) of Avon’s
outstanding 6.950% Notes due 2043 from 5:00 P.M. New York City time, on
July
25, 2019
to 5:00 P.M. New York City time, on July 30, 2019 (as amended hereby, the “2043s
Expiration Date”)
. 2043s Holders who have previously delivered consents in connection with the 2043s Consent Solicitation
do not need to redeliver such consents or take any other action in response to this announcement in order to consent to the 2043s
Consent Solicitation.
Except
as set forth herein with respect to the 2043s Expiration Date, the terms and conditions of the Consent Solicitations, as well
as the proposed amendments to the indentures governing the Notes, remain the same as set forth and described in the Consent Solicitation
Statement.
Citigroup
Global Markets Inc. (“Citi”), Banco Bradesco BBI S.A. (“Bradesco BBI”) and Itau BBA USA Securities, Inc.
(“Itau BBA”) are acting as the Solicitation Agents for the Consent Solicitations.
D.F.
King & Co., Inc.
is acting as the Information and Tabulation Agent for the Consent Solicitations.
Questions or requests for assistance related to the Consent Solicitations or for additional copies of the Consent Solicitation
Statement may be
directed
to Citi at +1 (212) 723-6106 (banks and brokers) and +1 (800) 558-3745 (all others, toll free), Bradesco BBI at +1
(646)
432-6643 (collect), Itau BBA at
+1 (888) 770-4828 (toll free) and
+1 (212) 710-6749
(collect),
or to D.F. King & Co., Inc. at +1 (212) 269-5550 (banks and brokers), +1
(866) 406-2285 (all others, toll free) or email at avon@dfking.com. The Consent Solicitation Statement is available at:
www.dfking.com/avon.
Holders may also contact their broker, dealer, commercial bank, trust company or other nominee
for assistance concerning the Consent Solicitations. Holders are urged to review the Consent Solicitation Statement for the detailed
terms of the Consent Solicitations and the procedures for consenting to the Proposed COC Amendments (as defined in the Consent
Solicitation Statement).
About
the Company and the Issuer
Natura
is Brazil’s largest multinational cosmetics,
hygiene and beauty company in terms of market share, as of December 2018, according to Euromonitor International, with operations
in Asia, Europe, North America, Oceania, and South America,
operating under the
Natura,
The Body Shop and Aesop brands. To learn
more
, please visit the Company’s website
at https://natu.infoinvest.com.br/en.
For
130 years Avon has stood for women: providing innovative, quality beauty products which are primarily sold to women, through women.
Millions of independent Representatives across the world sell iconic Avon brands such as Avon Color and ANEW through their social
networks, building their own beauty businesses on a full- or part-time basis. Avon supports women’s empowerment, entrepreneurship
and well-being and has donated over $1 billion to women’s causes through Avon and the Avon Foundation. To learn more, please
visit the Issuer’s website at investor.avonworldwide.com/.
Forward-Looking
Statements
Disclosures
in this press release contain forward-looking statements. All statements, other than statements of historical facts, included
in this press release that address activities, events or developments that management expects, believes or anticipates will or
may occur in the future are forward-looking statements. Without limiting the generality of the foregoing, forward-looking statements
contained in this press release specifically include statements regarding the consummation of the Transaction (as defined in the
Consent Solicitation Statement), the Consent Solicitations, including the timing thereof, the Proposed COC Amendments and the
execution of the supplemental indentures. These statements are based on certain assumptions made by the Company and the Issuer
based on their management’s respective experience and perception of historical trends, current conditions, anticipated future
developments and other factors believed to be appropriate. Such statements are subject to a number of assumptions, risks and uncertainties,
many of which are beyond the control of
the Company
and the Issuer, which may cause actual results to differ materially from those implied or
expressed by the forward-looking statements. These include risks set forth in reports filed by
the Company
with
the
Brazilian Securities Commission (
Comissão de Valores Mobiliários
) and by
the
Issuer with the U.S. Securities and Exchange Commission. Any forward-looking statement applies only as of the date on which such
statement is made and neither
the Company
nor the Issuer intends to correct or update
any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.
Natura
Cosméticos S.A.
Media
Inquiries:
Marcelo
Behar, Corporate Affairs Officer Natura &Co
natura@brunswickgroup.com
Investor
Relations:
Viviane
Behar de Castro, Investor Relations Director, Natura &Co
RI@natura.net
NO
OFFER OR SOLICITATION
This
communication is for informational purposes and does not constitute an offer to sell or the solicitation of an offer to buy any
securities or a solicitation of any vote or approval, nor shall there be any sale of
securities
in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the
securities laws of such jurisdiction.
ADDITIONAL
INFORMATION AND WHERE TO FIND IT
This
communication is being made in respect of the proposed transaction involving Natura Holding S.A. (collectively with Natura Cosmeticos
S.A., “Natura”) and Avon Products, Inc. (“Avon”). In connection with the proposed transaction, Natura
will file with the Securities and Exchange Commission (“SEC”) a registration statement on Form F-4 that will include
a proxy statement of Avon and a prospectus of Natura. Natura and Avon also plan to file other documents with the SEC regarding
the proposed transaction and a joint proxy statement/prospectus will be mailed to shareholders of Avon. This communication is
not a substitute for any proxy statement, registration statement, proxy statement/prospectus or other documents that Natura and/or
Avon may file with the SEC in connection with the proposed transaction. BEFORE MAKING ANY VOTING OR INVESTMENT DECISION, INVESTORS
ARE URGED TO READ THE FORM F-4 AND THE JOINT PROXY STATEMENT/PROSPECTUS REGARDING THE PROPOSED TRANSACTION AND ANY OTHER RELEVANT
DOCUMENTS CAREFULLY IN THEIR ENTIRETY WHEN THEY BECOME AVAILABLE BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED
TRANSACTION. The Form F-4 and the joint proxy statement/prospectus, as well as other filings containing information about Natura
and Avon, will be available without charge at the SEC’s Internet site (www.sec.gov). Copies of the joint proxy statement/prospectus
can also be obtained, when available, without charge, from Natura’s website at www.NaturaeCo.com. Copies of the joint proxy
statement/prospectus can be obtained, when available, without charge from Avon’s website at www.AvonWorldwide.com.
PARTICIPANTS IN THE SOLICITATION
Natura
and Avon, their respective directors, executive officers and other members of their management and employees may be deemed to
be participants in the solicitation of proxies in connection with the proposed transaction. Information regarding the persons
who may, under the rules of the SEC, be deemed participants in the solicitation of proxies in connection with the proposed transaction,
including a description of their direct or indirect interests, by security holdings or otherwise, will be set forth in the joint
proxy statement/ prospectus and other relevant materials when they are filed with the SEC. Information regarding the directors
and executive officers of Natura is contained in Natura’s Reference Form for 2018, version 15, which was filed with the
Brazilian Securities Commission on April 24, 2019. Information regarding the directors and executive officers of Avon is contained
in Avon’s definitive proxy statement for its 2019 annual meeting of shareholders, filed with the SEC on April 2, 2019. These
documents can be obtained free of charge from the sources indicated above.
CAUTION
ABOUT FORWARD-LOOKING STATEMENTS
Statements
in this communication (or in the documents it incorporates by reference) that are not historical facts or information may be forward-looking
statements within the meaning of the Private Securities Litigation Reform Act of 1995. Among other things, these forward looking
statements may include statements regarding the proposed transaction involving Natura and Avon; beliefs relating to value creation
as a result of a proposed transaction involving Natura and Avon; the expected timetable for completing the transaction; benefits
and synergies of the transaction; future opportunities for the combined company; and any other statements regarding Avon’s
and Natura’s future beliefs, expectations, plans, intentions, financial condition or performance. In some cases, words such
as “estimate,” “project,” “forecast,” “plan,” “believe,” “may,”
“expect,” “anticipate,” “intend,” “planned,” “potential,” “can,”
“expectation,” “could,” “will,” “would” and similar expressions, or the negative
of those expressions, may identify forward-looking statements. These forward-looking statements are based on Natura’s and
Avon’s expectations and beliefs concerning future events and involve risks and uncertainties that may cause actual results
to differ materially
from
current expectations. These factors are difficult to predict accurately and may be beyond Natura’s and Avon’s control.
Forward-looking statements in this communication or elsewhere speak only as of the date made. New uncertainties and risks arise
from time to time, and it is impossible for Natura or Avon to predict these events or how they may affect Natura or Avon. Therefore,
you should not rely on any of these forward-looking statements as predictors of future events. Except as required by law, neither
Natura nor Avon has any duty to, and does not intend to, update or revise the forward-looking statements in this communication
or elsewhere after the date this communication is issued. In light of these risks and uncertainties, investors should keep in
mind that results, events or developments discussed in any forward-looking statement made in this communication may not occur.
Uncertainties and risk factors that could affect Natura’s and/or Avon’s future performance and cause results to differ
from the forward-looking statements in this communication include, but are not limited to, (a) the parties’ ability to consummate
the transaction or satisfy the conditions to the completion of the transaction, including the receipt of shareholder approvals
and the receipt of regulatory approvals required for the transaction on the terms expected or on the anticipated schedule; (b)
the parties’ ability to meet expectations regarding the timing, completion and accounting and tax treatments of the transaction;
(c) the possibility that any of the anticipated benefits of the proposed transaction will not be realized or will not be realized
within the expected time period; (d) the risk that integration of Avon’s operations with those of Natura will be materially
delayed or will be more costly or difficult than expected; (e) the failure of the proposed transaction to close for any other
reason; (f) the effect of the announcement of the transaction on customer and consultant relationships and operating results (including,
without limitation, difficulties in maintaining relationships with employees or customers); (g) dilution caused by Natura’s
issuance of additional shares of its common stock in connection with the transaction; (h) the possibility that the transaction
may be more expensive to complete than anticipated, including as a result of unexpected factors or events; (i) the diversion of
management time on transaction-related issues; (j) the possibility that the intended accounting and tax treatments of the proposed
transactions are not achieved; (k) those risks described in Section 4 of Natura’s Reference Form for 2018, version 15, which
was filed with the Brazilian Securities Commission on April 24, 2019; and (l) those risks described in Item 1A of Avon’s
most recently filed Annual Report on Form 10-K and subsequent reports on Forms 10-Q and 8-K.
Avon Products (NYSE:AVP)
Historical Stock Chart
From Aug 2024 to Sep 2024
Avon Products (NYSE:AVP)
Historical Stock Chart
From Sep 2023 to Sep 2024